.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The ACCORD Blood Pressure trial compared an intensive systolic blood-pressure target below 120 mmHg with a standard target below 140 mmHg in people with type 2 diabetes. Intensive treatment did not significantly reduce the primary composite of major cardiovascular events, although stroke was reduced. Treatment was associated with more serious adverse events attributed to blood-pressure lowering. The study is important for clinicians because patients with diabetes are heterogeneous and may derive different absolute benefits from tighter pressure control depending on baseline cardiovascular risk. For general physicians, the practical message is to individualize targets rather than extrapolate SPRINT wholesale into every patient with diabetes. Accurate measurements, assessment of albuminuria, kidney function and cardiovascular disease, and monitoring for orthostatic symptoms are essential. The study also illustrates that intensification should be judged on a balance of benefits and harms, not on the achievement of a numeric target alone.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The ACCORD Blood Pressure trial compared an intensive systolic blood-pressure target below 120 mmHg with a standard target below 140 mmHg in people with type 2 diabetes. Intensive treatment did not significantly reduce the primary composite of major cardiovascular events, although stroke was reduced. Treatment was associated with more serious adverse events attributed to blood-pressure lowering. The study is important for clinicians because patients with diabetes are heterogeneous and may derive different absolute benefits from tighter pressure control depending on baseline cardiovascular risk. For general physicians, the practical message is to individualize targets rather than extrapolate SPRINT wholesale into every patient with diabetes. Accurate measurements, assessment of albuminuria, kidney function and cardiovascular disease, and monitoring for orthostatic symptoms are essential. The study also illustrates that intensification should be judged on a balance of benefits and harms, not on the achievement of a numeric target alone.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
